Skip to main content

Table 3 Prognostic factors affecting survival on univariate analysis

From: The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities

Factor 1-yr. survival rate (%) Hazard ratio (95% confidence interval) p
Age    
60 y.o. 41.2 1.293(0.343-4.882) 0.7
 < 60 y.o. 60   
Gender    
 Male 44.4 0.427(0.054-3.344) 0.42
 Female 55.6   
ECOG    
 0 66.7   
 1 47.1 1.656(0.209-13.085) 0.63
 2 50 2.155(0.134-34.555) 0.59
BCLC    
 B 50   
 C 50 0.915(0.117-7.176) 0.93
Vascular extension (PVTT & IVCTT)    
 Yes 37.5 4.920(0.628-38.559) 0.13
 No 83.3   
Child-Pugh score    
 A 55   
 B 0 17.303(2.301-130.129) 0.01
Hepatitis virus    
 B 50   
 C 25 1.938(0.483-7.774) 0.35
Non B non C 66.67 0.517(0.104-2.569) 0.42
AFP (IU/mL)    
 <1500 60   
1500 28.6 2.920(0.869-9.809) 0.08
Tumor location    
 Right 52.38   
 Left 0 7.629(0.783-74.297) 0.08
Tumor type    
 Solitary 54.6   
 Multiple 50 1.447(0.387-5.410) 0.58
 Diffuse 33.3 2.895(0.554-15.129) 0.21
Tumor size    
 10 cm 57.4   
 >10 cm 46.67 1.252(0.331-4.729) 0.74
Radiation dose    
 40 Gy 68.75   
 < 40 Gy 0 7.922(2.180-28.780) 0.01
Pre-SBRT treatment    
 Yes 66.7   
 No 38.5 2.576(0.679-9.777) 0.16
Post-SBRT treatment    
 Yes 66.7   
 N0 43.8 2.056(0.443-9.542) 0.36